Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Argent BiopharmaASX:RGT +6.45% Days Inventory is 0.00 as of Jun. 2026. The stock has 9 warning signs investors should review. Among 922 Drug Manufacturers companies, Argent Biopharma ranks worse than 93.49% on this metric.
The historical rank and industry rank for Argent Biopharma's Days Inventory or its related term are showing as below:
ASX:RGT'
s Days Inventory Range Over the Past 10 Years
Min: 71.03 Med: 409.69 Max: 1855.42
Current: 419.48
During the past 13 years, Argent Biopharma's highest Days Inventory was 1855.42. The lowest was 71.03. And the median was 409.69.
ASX:RGT's Days Inventory is ranked worse than 93.49% of 922
companies
in the Drug Manufacturers industry
Industry Median: 165.29
vs ASX:RGT: 419.48
Argent Biopharma's Days Inventory
declined
from Jun. 2025 (316.97) to Jun. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Argent Biopharma (ASX:RGT) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Argent Biopharma's Inventory Turnover for the
six
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Argent Biopharma's Inventory to Revenue for the
six
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Argent Biopharma Days Inventory Related Terms
Argent Biopharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (ASX:RGT) has a Days Inventory of 0.00 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Argent Biopharma and its competitors. Over the past decade, Argent Biopharma's Days Inventory has ranged from 71.03 to 1,855.42. According to the industry distribution chart, Argent Biopharma ranks #862 out of 922 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Argent Biopharma's Days Inventory too high?
Argent Biopharma's current Days Inventory is 0.00. Over the past 10 years, this metric has ranged from a low of 71.03 to a high of 1,855.42. Based on the distribution chart, Argent Biopharma ranks #862 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #862 out of 922 companies for Days Inventory. This places Argent Biopharma in the lower half of its industry. The industry median Days Inventory is 165.29. Historically, Argent Biopharma's own Days Inventory has ranged from 71.03 to 1,855.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.29, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (ASX:RGT) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.03 — trading 230% above its estimated fair value. The current Days Inventory is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Argent Biopharma (ASX:RGT), the current Days Inventory is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RGT has been successfully added to your 
